

Comparative Efficacy of Zanubrutinib Versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

PS1581

Talha Munir,¹ Keri Yang,² Sheng Xu,³ Rhys Williams,² Mazyar Shadman⁴

¹Leeds Teaching Hospital NHS Trust, Leeds, West Yorkshire, UK; ²BeOne Medicines Ltd., USA, San Carlos, CA, USA; ³BeOne Medicines Ltd., Shanghai, China; ⁴Fred Hutchinson Cancer Center and University of Washington, Seattle, WA, USA

CONCLUSIONS

- This MAIC examined the relative efficacy of zanubrutinib versus acalabrutinib plus the B-cell lymphoma-2 inhibitor venetoclax (AV) and demonstrated a significant progression-free survival (PFS) advantage for zanubrutinib over AV regimen
- Results should be interpreted with considerations of typical MAIC model assumptions. Future analyses upon trial data maturation are warranted

BACKGROUND

- In treatment-naïve (TN) CLL, the efficacy of continuous zanubrutinib has been investigated in the phase 3 SEQUOIA trial (NCT03336333)^{1,2}
- Efficacy of fixed duration combination regimen AV was evaluated in the phase 3 AMPLIFY trial (NCT03836261), with interim analysis results first presented in Dec 2024³ and published in Feb 2025⁴


OBJECTIVES

- In the absence of head-to-head clinical trials, an anchored matching-adjusted indirect comparison (MAIC) was conducted to investigate the comparative efficacy of zanubrutinib and AV in patients with low-risk TN CLL (without del(17p) or *TP53* mutations)

METHODS

- This MAIC was conducted using datasets with similar median follow-ups (SEQUOIA, 43.7 months; AMPLIFY, 41.0 months)
- With the assumption of bendamustine plus rituximab (BR) and fludarabine plus cyclophosphamide and rituximab (FCR)/BR treated as common control arms, SEQUOIA and AMPLIFY can be linked through FCR/BR and the comparison of zanubrutinib and AV was conducted in an anchored MAIC
- Individual patient data of low-risk (without del(17p) or *TP53* mutations) zanubrutinib patients in SEQUOIA were re-weighted to match the key population characteristics of AMPLIFY (**Figure 1**)
- Population adjustments considered prognostic factors or effect modifiers, including age, sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS), disease stage, del(11q), and immunoglobulin heavy chain variable (IGHV) gene mutation status (**Table 1**)
- Reconstructed individual patient data for AMPLIFY were generated from digitized Kaplan-Meier (KM) curves of progression-free survival (PFS)
- Weighted Cox proportional hazard regression was used to derive relative treatment effect estimates for PFS
- Sensitivity analyses were conducted in model scenarios of different matching variables
- At the time of this abstract submission, an anchored MAIC was conducted based on data availability of interim analysis of AMPLIFY³ that reported only independent review committee (IRC)-assessed PFS (IRC-PFS) and common control arm of FCR/BR. Based on data availability of the AMPLIFY publication from 2025,⁴ this poster presents analysis of INV-PFS, as well as additional sensitivity analysis of IRC-PFS, and an unanchored MAIC without the FCR/BR common control arm assumption

Figure 1. Overall Methodology Details



RESULTS

Base Case

- After population adjustment, the effective sample size (ESS) for SEQUOIA was 126 (**Table 2**)

Table 2. Baseline Characteristics of Low-Risk Patients in SEQUOIA Pre- and Post-Matching and in AMPLIFY

Population characteristic	AMPLIFY	SEQUOIA	
	N=581	Pre-matching N=389	Post-matching ESS=126
Age >65 (vs ≤65)	26.8%	78.7%	26.8%
Male	64.5%	61.7%	64.5%
ECOG PS=0-1 (vs 2)	91.8%	93.3%	91.8%
Binet stage AB or Rai 0-II (vs C or III-IV)	56.2%	70.2%	56.2%
Del(11q)	17.6%	19.5%	17.6%
IGHV unmutated	58.6%	52.7%	58.6%

Note: Unweighted population included only patients with non-missing baseline characteristics regarding all selected matching factors. del(11q), chromosome 11q deletion; ECOG PS, Eastern Cooperative Oncology Group performance status; ESS, effective sample size; IGHV, immunoglobulin heavy chain variable.


INV-PFS

- The unadjusted comparison of INV-PFS for zanubrutinib in SEQUOIA vs AV in AMPLIFY demonstrated a significant treatment benefit for zanubrutinib with hazard ratio (HR) of 0.47 (95% confidence interval [CI]: 0.28-0.77; *P*=.003)
- Population-adjusted INV-PFS for zanubrutinib vs AV indicated superior INV-PFS in favor of zanubrutinib with HR of 0.26 (95% CI: 0.13-0.54; *P*=.0003) (**Figure 2**)
- The 36-month PFS rate for zanubrutinib was 85.6% before matching and 88.5% after matching in the base case, compared with 76.5% for AV (**Table 3**)

Sensitivity Analyses

- Sensitivity analyses showed consistent results in model scenarios of different matching variables (**Table 4**) as well as IRC-PFS (HR=0.23, 95% CI: 0.12-0.48, *P*<.0001) and in unanchored MAIC without the common FCR/BR control arm assumption (HR=0.44, 95%CI: 0.21-0.89, *P*=.0220)

Figure 2. KM Plot for Reweighted SEQUOIA and AMPLIFY



AV, acalabrutinib plus venetoclax; BR, bendamustine + rituximab; FCR, fludarabine-cyclophosphamide-rituximab; INV-PFS, investigator-assessed progression-free survival; KM, Kaplan-Meier.

Table 3. Landmark PFS Rates

Time (months)	SEQUOIA zanubrutinib (INV-PFS)	SEQUOIA BR (INV-PFS)	AMPLIFY AV ^a (INV-PFS)	AMPLIFY FCR/BR ^a (INV-PFS)	AMPLIFY AV ^b (IRC-PFS)	AMPLIFY FCR/BR ^b (IRC-PFS)
12	97%	83.6%	96%	88%	95%	88%
24	94.2%	71.8%	91%	79%	88%	79%
36	88.5%	47.8%	79%	66%	77%	67%
48	86.7%	32.2%	67%	52%	64%	49%

^aEstimates are calculated from digitized KM curves. AV, acalabrutinib plus venetoclax; BR, bendamustine + rituximab; FCR, fludarabine-cyclophosphamide-rituximab; INV-PFS, investigator-assessed progression-free survival; IRC-PFS, independent review committee-assessed progression-free survival; KM, Kaplan-Meier; PFS, progression-free survival.

Table 4. INV-PFS HR Summary Table

HR INV-PFS zanubrutinib vs AV (95% CI, <i>P</i> value)	
Main analysis	
Unadjusted (low-risk)	0.47 (0.28-0.77, <i>P</i> =.003)
Base case	0.26 (0.13-0.54, <i>P</i> =.0003)
Sensitivity analyses	
S1	0.15 (0.07-0.34, <i>P</i> <.0001)
S2	0.26 (0.13-0.54, <i>P</i> =.0003)
S3	0.73 (0.29-1.84, <i>P</i> =.4992)
S4	0.22 (0.11-0.47, <i>P</i> =.0001)
S5	0.49 (0.27-0.86, <i>P</i> =.014)
S6	0.43 (0.15-1.21, <i>P</i> =.1092)
S7	0.30 (0.15-0.61, <i>P</i> =.0009)
S8	0.45 (0.26-0.76, <i>P</i> =.0033)
S9	0.27 (0.13-0.56, <i>P</i> =.0004)
S10	0.29 (0.14-0.59, <i>P</i> =.0008)
S11	0.27 (0.13-0.54, <i>P</i> =.0003)
S12	0.27 (0.14-0.54, <i>P</i> =.0002)
S13	0.27 (0.13-0.54, <i>P</i> =.0002)

Note: bolded values indicate *P*<.05. AV, acalabrutinib plus venetoclax; CI, confidence interval; HR, hazard ratio; INV-PFS, investigator-assessed progression-free survival.

DISCUSSION

- In the absence of head-to-head comparative trials, the indirect comparison statistical analyses were applied to compare efficacy of zanubrutinib vs AV
- Results should be interpreted with considerations of inherent limitations of indirect comparison, such as MAIC model assumptions, ie, the assumption that cross-trial differences in patient populations can be entirely explained by matching variables

REFERENCES

- Tam CS, et al Lancet Oncol. 2022;23:1031-1043.
- Munir T, et al Poster session presented at: EHA 2023; 2023 June 8-11; Frankfurt, Germany.
- Brown JR, et al Blood. 2024;144(Supplement 1):1009.
- Brown JR, et al N Engl J Med. 2025;392(8):748-762.

DISCLOSURES

TM: Consulting or advising roles for Janssen-Cilag, AstraZeneca, BeOne, SOBI, Roche, AbbVie, Alexion Pharmaceuticals, and Lilly; speakers' bureau participation for AbbVie, Janssen-Cilag, Gilead Sciences, Alexion Pharmaceuticals, AstraZeneca, and SOBI; and travel, accommodations, or expenses from Janssen-Cilag, AbbVie, Alexion Pharmaceuticals, and AstraZeneca. **KY:** Employment and equity holder in BeOne. **SX:** Employment and equity holder in BeOne. **RW:** Employment and equity holder in BeOne. **MS:** Employment with Bristol Myers Squibb; consulting or advising roles for AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeOne, Bristol Myers Squibb/Celgene, MorphoSys, Kite (a Gilead company), Fate Therapeutics, Lilly, Genmab, Merck, Nurix, and ADC Therapeutics; research funding from Pharmacyclics, Acerta Pharma, Merck, TG Therapeutics, BeOne, Celgene, Genentech, MustangBio, AbbVie, Sunesis Pharmaceuticals, Bristol Myers Squibb/Celgene, Genmab, and Vincerx Pharma; and stock options in Koi Biotherapeutics.

ACKNOWLEDGEMENTS

Medical writing support provided by SNELL Medical Communication, Inc. This study was funded by BeOne Medicines Ltd.